Most inherited cases stem from DNA repair and tumor-suppressor genes that lose their ability to patch routine errors or rein in uncontrolled growth, letting breast cells divide without the usual checks. BRCA1 and BRCA2 carry the highest known lifetime risks, while PALB2, TP53, CDH1, ATM, and CHEK2 add meaningful risk on modern multigene panels.
This overview is for anyone mapping a personal or family history of breast cancer and weighing genetic testing for breast cancer. You’ll get a working map of hereditary breast cancer genes, the risk ranges they carry, and how the results shape real decisions.
The Genetic Landscape of Breast Cancer
Most breast cancers are sporadic, arising from acquired mutations during a lifetime rather than from a gene passed down at birth. Only about 5 to 10 percent of all breast cancers and roughly 15 to 20 percent of familial clusters trace to a single high-risk gene mutation, and the rest come from aging, hormone exposure, lifestyle, and many small-effect variants combined into a polygenic risk score.
A smaller group falls under Hereditary Breast and Ovarian Cancer Syndrome, or HBOC, the umbrella label for the best-characterized inherited patterns. Recognizing which category fits your family changes the conversation from general advice to specific risk numbers and specific screening plans.
Inherited vs. Acquired Mutations
An inherited mutation sits in every cell of the body from birth and can be passed to the next generation. An acquired, or somatic, mutation happens in breast tissue at some point during life and lives only inside the tumor. Both can drive cancer, but they carry very different implications for family members and for the kind of genetic testing that helps.
The Role of Tumor Suppressor Genes and DNA Repair
Many of the high-risk genes involved in hereditary breast cancer, including BRCA1 and BRCA2, encode proteins that repair double-strand DNA breaks through a process called homologous recombination. When one copy is already mutated, a single additional hit to the working copy can disable repair and let damaged cells divide unchecked, which is the mechanism behind the steep lifetime risks these genes carry.
With that mechanism in mind, BRCA1 and BRCA2 deserve a closer look as the most powerful inherited drivers known today.
BRCA1 and BRCA2: The High-Penetrance Drivers
BRCA1 and BRCA2 remain the two genes most people associate with hereditary breast cancer, and for good reason. Together they account for the largest share of clearly inherited cases and carry the highest known lifetime risks, with BRCA1-associated tumors more often triple-negative and BRCA2-associated tumors more often estrogen receptor positive.
| Feature | BRCA1 | BRCA2 |
|---|---|---|
| Lifetime breast cancer risk (female) | 55 to 72 percent | 45 to 69 percent |
| Typical tumor subtype | More often triple-negative | More often estrogen receptor positive |
| Ovarian cancer risk | Elevated, roughly 40 to 50 percent lifetime | Elevated, roughly 15 to 25 percent lifetime |
| Male breast cancer risk | Slightly above average | Clearly elevated, around 5 to 10 percent |
| Other associated cancers | Pancreatic, fallopian tube | Pancreatic, prostate, melanoma |
| Inheritance pattern | Autosomal dominant | Autosomal dominant |
Inheritance follows an autosomal dominant pattern, which means a carrier has a 50 percent chance of passing the variant to each child regardless of sex. A negative family history on one side does not rule out a mutation, since the variant can travel silently through fathers as easily as mothers.
Why These Two Genes Matter Most
Both BRCA1 and BRCA2 produce proteins essential for accurate DNA repair. A working copy can keep pace with everyday damage; a broken copy cannot. Over years of cell division, unrepaired breaks accumulate, and the odds of a malignant transformation climb sharply, which is why carriers often face earlier screening and, in some cases, risk-reducing surgery well before any cancer appears.
Beyond BRCA: Other Genes Linked to Hereditary Risk
BRCA1 and BRCA2 are the headline names, but modern multigene panels routinely flag variants in several other genes, and each carries a different lifetime risk and a different clinical picture. You’ll see PALB2, TP53, and CDH1 grouped as high-penetrance additions, with ATM and CHEK2 sitting at moderate penetrance.
High-Penetrance Genes Outside BRCA
Germline TP53 mutations, the genetic hallmark of Li-Fraumeni syndrome, can push lifetime breast cancer risk as high as 90 percent and add risk for sarcomas, brain tumors, and adrenal cancers. CDH1 mutations specifically predispose carriers to lobular breast cancer at roughly 39 to 52 percent lifetime risk and to diffuse gastric cancer. PALB2 carriers face a 33 to 58 percent lifetime breast cancer risk, climbing steeply when a strong family history is present.
Moderate-Penetrance Genes
ATM and CHEK2 each raise breast cancer risk more modestly, typically by a factor of 1.5 to 3 over the general population, and risk rises further when combined with a strong family history or with radiation exposure. CHEK2 1100delC is more common in people of Northern European ancestry. These genes do not usually trigger the same aggressive screening protocols as BRCA mutations, but they still shape decisions about mammography timing and risk-reducing strategies.
Once inherited risk extends beyond those two genes, it helps to separate germline from somatic changes, since HER2 works through an entirely different pathway.
| Gene | Approximate Lifetime Risk | Notable Features |
|---|---|---|
| TP53 | Up to 90 percent | Li-Fraumeni syndrome; multiple cancer types |
| PALB2 | 33 to 58 percent | Risk climbs with family history |
| CDH1 | 39 to 52 percent | Lobular breast cancer; gastric cancer risk |
| ATM | Moderate (roughly 1.5 to 3x average) | Higher when combined with family history |
| CHEK2 | Moderate (roughly 1.5 to 3x average) | 1100delC variant common in Northern European ancestry |
How Somatic Mutations Like HER2 Differ
HER2-positive breast cancer sounds genetic, but the HER2 (also called ERBB2) change lives only inside tumor cells. Roughly 20 percent of breast cancers show HER2 amplification, a somatic event that drives aggressive tumor growth and shapes treatment choices rather than family risk.
Germline vs. Somatic in Practice
Somatic mutations guide targeted treatment plans but are not inherited, which is why HER2 status is tested on tumor tissue from a biopsy, not on a blood sample drawn for family risk assessment. A woman can have a HER2-positive tumor with no relevant family history, and her children do not inherit the HER2 amplification.
The distinction matters at the clinic. Blood-based genetic testing looks for inherited risk in healthy cells. Tumor profiling looks for acquired drivers inside the cancer itself. The two tests answer different questions, and confusing them can lead to wrong assumptions about family risk.
Who Should Consider Genetic Testing
National Comprehensive Cancer Network guidance recommends genetic testing for breast cancer based on a combination of personal history, family history, ancestry, and tumor features. You do not need to tick every box to qualify, and many people qualify on personal history alone.
Common Triggers for Testing
Clinicians usually suggest a genetic testing referral when one or more of the following situations apply:
- Personal history of breast cancer at age 50 or younger, or triple-negative disease at any age.
- Multiple primary cancers, such as breast and ovarian, or bilateral breast cancer.
- Family history of breast, ovarian, pancreatic, or prostate cancer in close relatives, especially at young ages.
- Ashkenazi Jewish ancestry, where founder mutations in BRCA1 and BRCA2 are more common.
- Male breast cancer in any close relative, which is itself a red flag.
- Limited or unknown family history combined with early-onset disease, since a negative family record does not rule out inherited risk.
Testing usually uses a multigene panel covering BRCA1, BRCA2, and other high- and moderate-penetrance genes, all from a single blood or saliva sample.
A negative result does not eliminate risk, especially when family history remains unexplained. Pre-test counseling and post-test interpretation with a genetic counselor matter here, since the choice of test and the meaning of the results depend on your full picture.
Knowing whether testing fits your situation leads directly to the harder part: making sense of what the lab actually returns.
Reading the Results and Acting on Them
A positive pathogenic variant, meaning a clearly harmful mutation, opens several options that your care team can tailor to your situation. Enhanced screening with breast MRI alternating with mammography often starts at a younger age. Risk-reducing surgery, particularly bilateral mastectomy, sharply lowers breast cancer risk in BRCA1 and BRCA2 carriers. Chemoprevention with medications a clinician may recommend can also reduce risk in some carriers.
What a Variant of Uncertain Significance Means
When a lab identifies a VUS, it has detected a genetic change but lacks enough evidence to classify it as either harmful or benign. A VUS should not drive clinical decisions on its own, and the result may be reclassified as more data accumulate over the years. Keeping your report on file and checking back with your genetic counselor every few years is the practical move.
Practical Next Steps After a Positive Result
Carriers can explore reproductive planning, including preimplantation genetic testing during IVF to reduce the chance of passing the variant to children. Cascade testing for at-risk relatives, starting with siblings, parents, and adult children, is one of the highest-value actions available. Many carriers also qualify for clinical trials of new screening methods or prevention strategies, which can broaden your options over time.
Limits remain: not every carrier develops cancer, and not every familial cluster has a known genetic cause. A clear mutation is information, not a sentence.
Bottom Line
The clearest signal from research is that inherited risk concentrates in a small set of well-studied genes, with BRCA1 and BRCA2 carrying the heaviest burden and a growing list of moderate-penetrance genes shaping decisions in between. Somatic markers like HER2 live in the tumor itself and answer a different question about treatment, not family.
Knowing which category you or your family falls into, and acting on that knowledge with a genetic counselor, is where the real value of this information lives.
FAQ
Which genes are most commonly linked to breast cancer?
BRCA1 and BRCA2 are the most common high-risk genes, accounting for the largest share of clearly hereditary cases. PALB2, TP53, CDH1, ATM, and CHEK2 are also routinely included on modern multigene panels because each raises risk meaningfully.
How are BRCA1 and BRCA2 inherited?
Both follow an autosomal dominant pattern. Each child of a carrier has a 50 percent chance of inheriting the variant regardless of sex, and the mutation can pass silently through fathers as easily as mothers.
What percentage of breast cancer is hereditary?
About 5 to 10 percent of all breast cancers and roughly 15 to 20 percent of familial clusters trace to a single inherited gene mutation. Most cases are sporadic or driven by many small-effect variants combined into a polygenic risk score.
Should I get genetic testing if breast cancer runs in my family?
Strong family history, especially early-onset breast cancer, ovarian cancer, male breast cancer, or Ashkenazi Jewish ancestry, is a common trigger for testing. A genetic counselor can review your personal and family history and recommend the right panel.
What other cancers are BRCA mutations associated with?
BRCA1 raises the risk of ovarian, fallopian tube, and pancreatic cancers. BRCA2 raises the risk of ovarian, pancreatic, prostate, and male breast cancers, along with melanoma in some families.
Can you have a breast cancer gene and never get cancer?
Yes. Penetrance is high but not absolute, meaning many carriers live cancer-free. A positive result signals elevated risk and shapes screening, but it does not predict cancer with certainty.
